TG Therapeutics Inc (NASDAQ:TGTX) – Jefferies Financial Group raised their FY2023 earnings per share estimates for shares of TG Therapeutics in a note issued to investors on Tuesday, April 2nd. Jefferies Financial Group analyst C. Howerton now forecasts that the biopharmaceutical company will earn $0.40 per share for the year, up from their previous estimate of $0.30. Jefferies Financial Group has a “Buy” rating and a $8.00 price target on the stock.
A number of other analysts have also recently commented on TGTX. BidaskClub upgraded shares of TG Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 2nd. B. Riley initiated coverage on shares of TG Therapeutics in a report on Tuesday, January 8th. They set a “buy” rating and a $10.00 target price on the stock. HC Wainwright restated a “buy” rating on shares of TG Therapeutics in a report on Tuesday, January 22nd. Zacks Investment Research cut shares of TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 30th. Finally, ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, February 28th. One investment analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. TG Therapeutics presently has a consensus rating of “Buy” and an average target price of $14.07.
A number of institutional investors have recently made changes to their positions in the stock. Teachers Advisors LLC boosted its stake in TG Therapeutics by 4.3% in the 3rd quarter. Teachers Advisors LLC now owns 127,405 shares of the biopharmaceutical company’s stock worth $713,000 after purchasing an additional 5,221 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in TG Therapeutics by 10.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 71,312 shares of the biopharmaceutical company’s stock worth $292,000 after purchasing an additional 6,812 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in TG Therapeutics by 3.8% in the 3rd quarter. Bank of New York Mellon Corp now owns 286,843 shares of the biopharmaceutical company’s stock worth $1,606,000 after purchasing an additional 10,518 shares in the last quarter. Forbes J M & Co. LLP bought a new position in TG Therapeutics in the 4th quarter worth about $44,000. Finally, LPL Financial LLC bought a new position in TG Therapeutics in the 4th quarter worth about $49,000. Institutional investors own 55.59% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Read More: What is Net Asset Value (NAV)?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.